Through
12/30
Cancer Research
Lidocaine may be able to kill certain cancer cells by activating bitter taste receptors
Lidocaine may be able to kill certain cancer cells by activating bitter taste receptors
A preclinical Penn Medicine study explains the previously observed anti-cancer effect of the common anesthetic drug.
Decentralizing cancer screenings
Decentralizing cancer screenings
A Projects for Progress team in the Abramson Cancer Center continues to work with the West Philadelphia community to bring cancer screenings out of clinical settings.
Penn Medicine studies unlock new insights into gene therapy
Penn Medicine studies unlock new insights into gene therapy
The studies on AAV-based gene therapies in non-human primates suggest that integration into human DNA is unlikely to drive cancer mutations.
How cell developmental biology fits into the future of medicine
How cell developmental biology fits into the future of medicine
Ben Stanger, the Hanna Wise Professor in Cancer Research and professor of medicine and cell and developmental biology, discusses his research and publishing his first book, ‘From One Cell: A Journey into Life’s Origins and the Future of Medicine.’
A ‘thermometer’ tool to measure tumor growth between scans
A ‘thermometer’ tool to measure tumor growth between scans
Researchers at Penn Medicine have developed a first-ever tool that gives a real-time assessment of tumors to provide less uncertainty for patients worrying between scans.
Leveraging the body’s postal system to understand and treat disease
Leveraging the body’s postal system to understand and treat disease
An interdisciplinary team of researchers in the School of Engineering and Applied Science, Perelman School of Medicine, and School of Arts & Sciences has developed a technique that allows for characterization of both individual carrier and cargo for clinically important molecules.
Study shows promise for iNKT cell platform to treat cancer
Study shows promise for iNKT cell platform to treat cancer
Researchers from the School of Veterinary Medicine and Perelman School of Medicine have shown that invariant natural killer T cells from a healthy donor can persist in MHC-mismatched canines, demonstrating a reliable platform to inform human clinical trials.
Removing the barrier surrounding solid tumors clears path for T cells
Removing the barrier surrounding solid tumors clears path for T cells
Penn researchers uncover a new way to target solid tumors. Using CAR T cells to remove cancer-associated fibroblasts surrounding pancreatic tumors allows T cells to infiltrate and attack the tumor cells.
Genetic switch turns tumor suppressor into oncogene in colorectal cancer
Genetic switch turns tumor suppressor into oncogene in colorectal cancer
Researchers from the School of Veterinary Medicine have shown that an enzyme that suppresses early-stage colorectal cancer switches to become an oncogene as the cancer progresses.
An immunotherapy strategy against all blood cancers
An immunotherapy strategy against all blood cancers
Researchers at Penn Medicine have demonstrated a new potential treatment using CAR T cell therapy using a CRISPR base-editing to develop a method called “epitope editing.”
In the News
RNZ/Radio New Zealand
Trial results offer hope to Kiwis with ‘incurable’ blood cancer
Carl June of the Perelman School of Medicine praises New Zealand research into a new CAR T-cell cancer treatment for patients with blood cancer.
FULL STORY →
Philadelphia Inquirer
Emily Whitehead was the first child cured of cancer with therapy from Penn. She’s back as a freshman
Emily Whitehead of Philipsburg, Pennsylvania, the first child cured of leukemia with CAR-T cancer therapy, has returned to Penn as a first-year in the College of Arts and Sciences.
FULL STORY →
Stat
Vampiric cancer cells, a brain atlas, & alleged misconduct at Cassava
Research by Bo Li of the Perelman School of Medicine finds that cancer cells can use mitochondria to sap energy from T cells, resisting treatment and evading the body’s defenses.
FULL STORY →
New York Post
Why CAR T cell therapy is the cancer killer the world needs now
Research from Michael Mitchell of the School of Engineering and Applied Science has developed a new method to stop cytokine release during CAR T cell therapy, preventing some of its more dangerous side effects.
FULL STORY →
The Business Journals
Penn’s cell therapy pioneer Dr. Carl June shares $3M Breakthrough Prize in Life Sciences
Carl June of the Perelman School of Medicine has been awarded a $3 million Breakthrough Prize in life sciences for developing CAR-T therapy to treat cancer, with remarks from President Liz Magill.
FULL STORY →
USA Today
Cancer treatment has come far, fast: Better prevention, early detection, new treatment
Carl June of the Perelman School of Medicine was awarded a $3 million Breakthrough Prize in life sciences for developing CAR-T therapy to treat cancer.
FULL STORY →